Literature DB >> 20937190

MODS accreditation process for regional reference laboratories in Peru: validation by GenoType® MTBDRplus.

J Coronel1, M Roper, S Mitchell, E Castillo, N Gamarra, F Drobniewski, G Luna, A Mendoza, D A J Moore.   

Abstract

SETTING: Although considerable effort has been put into the development and evaluation of new diagnostics for tuberculosis (TB) and multidrug-resistant TB (MDR-TB), little attention has thus far been paid to the technical aspects of initiating quality-assured routine service use. For implementation of the microscopic-observation drug susceptibility (MODS) methodology in the Peruvian reference laboratory network, a laboratory accreditation process was devised; MODS results from an expert reference laboratory (Universidad Peruana Cayetano Heredia [UPCH]) were used as the standard against which implementing laboratory MODS results were judged to ensure that, prior to use for patient care, implementing laboratories achieved the same high performance with MODS as previously demonstrated in the research laboratory.
OBJECTIVE: To evaluate the validity of MODS-based accreditation and the concordance of MODS drug susceptibility testing (DST) with molecular testing.
DESIGN: Head-to-head comparison of MODS DST results from implementing Peruvian regional reference laboratories and the accrediting expert MODS laboratory (UPCH) with GenoType® MTBDRplus DST.
RESULTS: The concordance of phenotypic MODS rifampicin (RMP) DST with GenoType MTBDRplus was respectively 97.4%, 97.9% and 97.1% for the two implementing regional laboratories and UPCH, and respectively 94.7%, 95.7% and 94.6% for isoniazid (INH) DST.
CONCLUSION: High and consistent levels of MODS/MTBDRplus concordance for INH and RMP DST confirm the validity of the use of rapid methods as reference standards for accreditation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937190      PMCID: PMC3103710     

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  14 in total

1.  Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings.

Authors:  David A J Moore; Daniel Mendoza; Robert H Gilman; Carlton A W Evans; María-Graciela Hollm Delgado; Jose Guerra; Luz Caviedes; Daniel Vargas; Eduardo Ticona; Jaime Ortiz; Giselle Soto; Jose Serpa
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Girum Shiferaw; Yimtubezinash Woldeamanuel; Mekdes Gebeyehu; Feven Girmachew; Daniel Demessie; Eshetu Lemma
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

3.  Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa.

Authors:  Marinus Barnard; Heidi Albert; Gerrit Coetzee; Richard O'Brien; Marlein E Bosman
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

4.  Microscopic-observation drug-susceptibility assay for the diagnosis of TB.

Authors:  David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

5.  Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru.

Authors:  L Caviedes; T S Lee; R H Gilman; P Sheen; E Spellman; E H Lee; D E Berg; S Montenegro-James
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

6.  Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB.

Authors:  G S Ejigu; Y Woldeamanuel; N S Shah; M Gebyehu; A Selassie; E Lemma
Journal:  Int J Tuberc Lung Dis       Date:  2008-03       Impact factor: 2.373

7.  Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.

Authors:  Rose A Devasia; Amondrea Blackman; Carolyn May; Svetlana Eden; Teresa Smith; Nancy Hooper; Fernanda Maruri; Charles Stratton; Ayumi Shintani; Timothy R Sterling
Journal:  J Antimicrob Chemother       Date:  2009-03-28       Impact factor: 5.790

8.  Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

9.  Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation.

Authors:  Vladyslav Nikolayevskyy; Yanina Balabanova; Tatyana Simak; Nadezhda Malomanova; Ivan Fedorin; Francis Drobniewski
Journal:  BMC Clin Pathol       Date:  2009-03-10

Review 10.  Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis.

Authors:  Freddie Bwanga; Sven Hoffner; Melles Haile; Moses L Joloba
Journal:  BMC Infect Dis       Date:  2009-05-20       Impact factor: 3.090

View more
  5 in total

1.  Reliability of the MODS assay decentralisation process in three health regions in Peru.

Authors:  A Mendoza; E Castillo; N Gamarra; T Huamán; M Perea; Y Monroi; R Salazar; J Coronel; M Acurio; G Obregón; M Roper; C Bonilla; L Asencios; D A J Moore
Journal:  Int J Tuberc Lung Dis       Date:  2011-02       Impact factor: 2.373

2.  Training laboratory technicians from the Ethiopian periphery in the MODS technique enables rapid and low-cost diagnosis of Mycobacterium tuberculosis infection.

Authors:  Hila Elinav; Henry D Kalter; Luz Caviedes; Lawrence H Moulton; Eshetu Lemma; Andrea Rajs; Colin Block; Shlomo Maayan
Journal:  Am J Trop Med Hyg       Date:  2012-04       Impact factor: 2.345

3.  Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.

Authors:  Jose Gabriel Cornejo Garcia; Valentina Antonieta Alarcón Guizado; Alberto Mendoza Ticona; Edith Alarcon; Einar Heldal; David A J Moore
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

4.  Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment.

Authors:  J Coronel; M H Roper; C Herrera; C Bonilla; O Jave; C Gianella; I Sabogal; V Huancaré; E Leo; A Tyas; A Mendoza-Ticona; L Caviedes; D A J Moore
Journal:  Clin Microbiol Infect       Date:  2013-11-21       Impact factor: 8.067

5.  Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.

Authors:  Caroline Allix-Béguec; Irena Arandjelovic; Lijun Bi; Patrick Beckert; Maryline Bonnet; Phelim Bradley; Andrea M Cabibbe; Irving Cancino-Muñoz; Mark J Caulfield; Angkana Chaiprasert; Daniela M Cirillo; David A Clifton; Iñaki Comas; Derrick W Crook; Maria R De Filippo; Han de Neeling; Roland Diel; Francis A Drobniewski; Kiatichai Faksri; Maha R Farhat; Joy Fleming; Philip Fowler; Tom A Fowler; Qian Gao; Jennifer Gardy; Deborah Gascoyne-Binzi; Ana-Luiza Gibertoni-Cruz; Ana Gil-Brusola; Tanya Golubchik; Ximena Gonzalo; Louis Grandjean; Guangxue He; Jennifer L Guthrie; Sarah Hoosdally; Martin Hunt; Zamin Iqbal; Nazir Ismail; James Johnston; Faisal M Khanzada; Chiea C Khor; Thomas A Kohl; Clare Kong; Sam Lipworth; Qingyun Liu; Gugu Maphalala; Elena Martinez; Vanessa Mathys; Matthias Merker; Paolo Miotto; Nerges Mistry; David A J Moore; Megan Murray; Stefan Niemann; Shaheed V Omar; Rick T-H Ong; Tim E A Peto; James E Posey; Therdsak Prammananan; Alexander Pym; Camilla Rodrigues; Mabel Rodrigues; Timothy Rodwell; Gian M Rossolini; Elisabeth Sánchez Padilla; Marco Schito; Xin Shen; Jay Shendure; Vitali Sintchenko; Alex Sloutsky; E Grace Smith; Matthew Snyder; Karine Soetaert; Angela M Starks; Philip Supply; Prapat Suriyapol; Sabira Tahseen; Patrick Tang; Yik-Ying Teo; Thuong N T Thuong; Guy Thwaites; Enrico Tortoli; Dick van Soolingen; A Sarah Walker; Timothy M Walker; Mark Wilcox; Daniel J Wilson; David Wyllie; Yang Yang; Hongtai Zhang; Yanlin Zhao; Baoli Zhu
Journal:  N Engl J Med       Date:  2018-09-26       Impact factor: 91.245

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.